Company intelligence / Profile preview

Univer Product

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Univercells has developed a human rabies vaccine slated to enter Phase 1 clinical trials. They are also involved in strategic partnerships to pioneer oncology treatments. Their main impact is enabling faster, more affordable access to advanced therapies through innovative manufacturing platforms rather than developing proprietary therapeutics at late clinical stages.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineMonoclonal antibodyProtein biologicsViral vectorsRecombinant protein
Industry: Biotech

Partnerships

Serum Institute of IndiaOxford Cancer/Oxford Vaccine Group/Pandemic Sciences InstituteBio-Manguinhos/FiocruzBig Pharma collaborations via technology licensing/manufacturing partnerships

Beyond the preview

Go deeper on Univer Product.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Univer Product.

Explore the full profile